Shom Goel, M.D., Ph.D.
Affiliations: | Cancer Biology | Dana-Farber Cancer Institute, Boston, MA, United States |
Google:
"Shom Goel"Mean distance: 42746.4
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kudo R, Safonov A, Jones C, et al. (2024) Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell. 42: 1983 |
| Kudo R, Safonov A, Jones C, et al. (2024) Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell |
| Jovanovic B, Church SE, Gorman KM, et al. (2024) Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Fjermeros K, Ghannoum S, Geisler SB, et al. (2024) The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer. Future Oncology (London, England). 1-10 |
| Dietrich C, Trub A, Ahn A, et al. (2023) INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discovery |
| Tolaney SM, Goel S, Nadal J, et al. (2023) Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Tolaney SM, Goel S, Appiah AK, et al. (2023) Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study. Future Oncology (London, England) |
| Ali LR, Garrido-Castro AC, Lenehan PJ, et al. (2023) PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of Experimental Medicine. 220 |
| Goel S, Chandarlapaty S. (2022) Emerging Therapies for Breast Cancer. Cold Spring Harbor Perspectives in Medicine |
| Goel S, Tan AR, Rugo HS, et al. (2022) Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future Oncology (London, England) |